跳至主要内容
临床试验/NCT00734045
NCT00734045已完成不适用

Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples

Nanogen, Inc.2 个研究点 分布在 1 个国家目标入组 450 人开始时间: 2008年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Nanogen, Inc.
入组人数
450
试验地点
2
主要终点
StatusFirst CHF NT-proBNP test result

研究概览

简要总结

The primary objective of the study is to establish the correlation between NT-proBNP measurements in fresh human whole blood samples and those in plasma samples from the same study subjects, where said samples are collected in EDTA and Li-Hep anticoagulant tubes and measured by the StatusFirst™ CHF NT-proBNP device in conjunction with the DXpressTM Reader in a laboratory setting.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Have clinically confirmed heart failure (NYHA class I-IV) or have presented to an emergency room or clinic with signs, symptoms and/or risk factors suggestive of heart failure, OR
  • Be non-CHF controls greater than 45 years of age with no history of heart failure or cardiovascular disease.

排除标准

  • Be 45 years of age or younger

结局指标

主要结局

StatusFirst CHF NT-proBNP test result

时间窗: At presentation to study site (no follow-up)

次要结局

未报告次要终点

研究者

发起方
Nanogen, Inc.
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验